Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen Pulls Controversial Alzheimer's Drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

International Business Times

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Patent monopolies are not "free" market

Drug patent monopolies cost each family $5,000 per year

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review

The stock market rally erased weekly gains as the major indexes ended long win streaks amid rebounding yields. Datadog led earnings winners.

Investors Business Daily

Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout

Biogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But analysts noted Skyclarys' strong launch.

Investors Business Daily

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

Investors Business Daily

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder

Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Investors Business Daily

Do new Alzheimer's drugs actually help?

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Salon

FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected

Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.

Investors Business Daily

These Are The 5 Best Stocks Of The Year; Some You May Not Recognize

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

Investors Business Daily

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Improves; Tesla Stock Falls On Management Change

The stock market posted gains across the board with the Dow and S&P near the day's highs. Mattel stock gets a lift on "Barbie" movie sales.

Salon

FDA approves postpartum depression pill

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

Investors Business Daily

Stock Market Finishes Week Strong; Roku Stock Gains 31% After Company Posts Smaller Loss

The stock market held on to most of Friday's afternoon gains. A solar stock shined while an energy stock got burned.

Investors Business Daily

Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce

Biogen says it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion. Reata stock surged as Biogen stock gained ground.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

Investors Business Daily

IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout

Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears "very competitive" with Biogen's.

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Investors Business Daily

Dow Jones Futures Fall With Jobs Report Due; Meta Leads 7 Resilient Stocks

The jobs report looms with Treasury yields soaring. Meta is among stocks holding up as Threads had record first-day downloads.

Axios

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Roll Call

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Investors Business Daily

Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug

Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi.

1 2 3 4 5

People

Elon Musk

21,030 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations